Last reviewed · How we verify
placebo plus folic acid
Folic acid supplementation supports cellular methylation and nucleotide synthesis, while placebo provides a control baseline.
Folic acid supplementation supports cellular methylation and nucleotide synthesis, while placebo provides a control baseline. Used for Folic acid deficiency prevention, Periconceptional supplementation (pregnancy planning and early pregnancy).
At a glance
| Generic name | placebo plus folic acid |
|---|---|
| Sponsor | University Magna Graecia |
| Drug class | Vitamin supplement / Nutritional agent |
| Modality | Small molecule |
| Therapeutic area | Nutritional deficiency / Obstetrics / Hematology |
| Phase | FDA-approved |
Mechanism of action
Folic acid (vitamin B9) is an essential cofactor for one-carbon metabolism and DNA synthesis. In this formulation, it is combined with placebo as a comparator, likely used in clinical trials to evaluate the independent contribution of folic acid supplementation versus inert control. Folic acid deficiency can impair cell division and increase homocysteine levels, making supplementation relevant for pregnancy, anemia, and cardiovascular health.
Approved indications
- Folic acid deficiency prevention
- Periconceptional supplementation (pregnancy planning and early pregnancy)
Common side effects
- Gastrointestinal upset
- Allergic reactions (rare)
Key clinical trials
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer (PHASE3)
- Effect of Vitamin D and Folic Acid on Mild Cognitive Impairment (NA)
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (PHASE3)
- A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV. (NA)
- Validation of a Novel Functional Food Designed to Meet the Nutritional Needs of People Living With Parkinson's Disease (NA)
- A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo plus folic acid CI brief — competitive landscape report
- placebo plus folic acid updates RSS · CI watch RSS
- University Magna Graecia portfolio CI